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CASE REPoRT
CASE REPORT
A 67-year-old woman with no history of smoking pre-
sented with a 1-month complaint of headache and left hemi-
paresis. She also complained of a nonproductive cough and 
a weight loss of 15 pounds during the previous 3 months. 
She had a good performance status (PS 1) and no comor-
bidities. Magnetic resonance imaging of the brain revealed 
multiple ring-enhancing nodular lesions at the gray-white 
matter junction with marked surrounding edema, sugges-
tive of metastases (Fig. 1). The edema was causing sulcal 
effacement and midline deviation to the left. The patient 
was immediately started on a steroid (dexamethasone, 4 
mg orally every 6 hours), a proton-pump inhibitor (omepra-
zole, 40 mg daily), and a prophylactic anticonvulsant (phe-
nytoine, 100 mg every 8 hours). After 24 hours, she had 
achieved partial recovery from the left paresis and her 
headache had been alleviated. Thoracic computed tomog-
raphy (CT) scans revealed an irregular, heterogeneous, 
contrast-enhancing lung mass in the left upper lobe and left 
hilar, and mediastinal lymph node enlargements (Fig. 2). 
Abdominal and pelvic CT revealed no other abnormalities. 
A CT-guided lung biopsy was performed, and lung adeno-
carcinoma was confirmed. The adenocarcinoma harbored 
an epidermal growth factor receptor (EGFR) exon 19 dele-
tion (del E746-A750).
Despite the presence of symptoms and the large num-
ber of brain lesions (seven in total), we decided to start the 
patient on oral erlotinib (150 mg/day) instead of whole-
brain radiation therapy. There is evidence that omeprazole 
and phenytoine may reduce erlotinib absorption and activa-
tion, respectively.1 Nevertheless, these drugs were initially 
maintained, given the high risk of complications associated 
with the use of steroids and the possibility of seizures. The 
patient progressively recovered from her central nervous 
system-related symptoms; a remarkable response in all 
metastatic lesions, including resolution of the associated 
edema, sulcal effacement, and midline deviation, was dem-
onstrated by brain magnetic resonance imaging 6 weeks 
later (Fig. 1). A major response was also observed in the 
thorax (Fig. 2). The patient is currently at PS 0, with great 
tolerability and quality of life, and visits our clinic every 
4 weeks.
DISCUSSION
The EGFR tyrosine kinase inhibitors erlotinib and 
gefitinib are valid options before radiotherapy among 
patients with asymptomatic brain metastases that have 
arisen from non–small-cell lung cancers harboring sensitiz-
ing EGFR mutations.2 In such circumstances, the response 
rate is over 70%, median progression-free survival varies 
from 6.6 to 23.2 months, and overall survival ranges from 
12.9 to 19.8 months.3–5 Furthermore, disease control tends 
to be superior among patients with classic exon 19 dele-
tions, as compared to those with point mutations in exon 
21.4 It should be noted, however, that use of this approach 
for patients with symptomatic central nervous system 
metastases has only been rarely described in the literature. 
As illustrated by the reported case, selected patients with 
sensitizing EGFR mutations may also be primarily treated 
with targeted therapy. Considering that whole-brain radia-
tion therapy may delay systemic treatment and lead to sig-
nificant medium-term cognitive deficits, the favorable and 
rapid response to EGFR inhibitors makes them a feasible 
and attractive alternative, providing strict neurologic vigi-
lance is exercised.
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FIGURE 1. Axial contrast-enhanced fat-suppressed T1-weighted images before (left column) and after treatment (right col-
umn), showing remarkable reductions in both volumes of the multiple ring-enhancing nodular lesions at the gray-white matter 
junction and surrounding edema.
FIGURE 2. Chest computed tomography images of the 
tumor in the left upper lobe before (A) and after treatment 
(B), showing a major response to erlotinib.
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